THE ANTI-CD20 ANTIBODY RITUXIMAB REDUCES THE INFLAMMATORY AND PROTHROMBOTIC PROFILE OF LEUKOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS AND MODULATES THE ACTIVITY OF ENDOTHELIAL CELLS

被引：0
|
作者：
Cecchi, I. [1 ]
Perez-Sanchez, C. [2 ]
Ruiz-Limon, P. [2 ]
de la Rosa, I. Arias [2 ]
Abalos-Aguilera, M. C. [2 ]
Jimenez-Gomez, Y. [2 ]
Ortega, R. [2 ]
Collantes-Estevez, E. [2 ]
Escudero, A. [2 ]
Barbarroja, N. [2 ]
Sciascia, S. [1 ]
Lopez-Pedrera, C. [2 ]
机构：
[1] Coordinating Ctr Piemonte & Valle dAosta Network, Ctr Res Immunopathol & Rare Dis, Dept Clin & Biol Sci, Turin, Italy
[2] Univ Cordoba, Reina Sofia Hosp, IMIBIC, GC Rheumatol 5, Cordoba, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.4916
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0048
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [1] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
    Korhonen, Riku
    Moilanen, Eeva
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21
  • [2] The anti-CD20 antibody Rituximab reduces the Th17 response
    van de Veerdonk, Frank L.
    Lauwerys, Bernard
    DiPadova, Franco
    Marijnissen, Renoud J.
    Koenders, Marije I.
    Gutierrez-Roelens, Ilse
    Durez, Patrick
    Netea, Mihai G.
    van der Meer, Jos W. M.
    van den Berg, Wim B.
    Joosten, Leo A. B.
    [J]. CYTOKINE, 2009, 48 (1-2) : 98 - 98
  • [3] B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
    Shaw, T
    Quan, J
    Totoritis, MC
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 55 - 59
  • [4] Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
    Ng, CM
    Bruno, R
    Combs, D
    Davies, B
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07): : 792 - 801
  • [5] Modulation of gene expression profiles of pbmc in rheumatoid arthritis patients treated with anti-CD20 (rituximab)
    Drynda, S.
    Koczan, D.
    Thiesen, H. J.
    Kekow, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : A29 - A29
  • [6] The Anti-CD20 Antibody Rituximab Reduces the Th17 Cell Response
    van de Veerdonk, Frank L.
    Lauwerys, Bernard
    Marijnissen, Renoud J.
    Timmermans, Kim
    Di Padova, Franco
    Koenders, Marije I.
    Gutierrez-Roelens, Ilse
    Durez, Patrick
    Netea, Mihai G.
    van der Meer, Jos W. M.
    van den Berg, Wim B.
    Joosten, Leo A. B.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (06): : 1507 - 1516
  • [7] Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody
    Attia, Sabry M.
    Al-Hamamah, Mohammed A.
    Alotaibi, Moureq R.
    Alasmari, Abdullah F.
    Attia, Mohamed S. M.
    Ahmad, Sheikh F.
    Mahmoud, Mohamed A.
    Nadeem, Ahmed
    Ansari, Mushtaq A.
    Bakheet, Saleh A.
    [J]. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2023, 888
  • [8] THE INVESTIGATION OF INFLUENCE OF THE TREATMENT WITH ANTI-CD20 ANTIBODIES (RITUXIMAB) ON BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Dydykina, P.
    Dydykina, I.
    Devyataikina, A.
    Lukina, G.
    Smimov, A.
    Nasonov, E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S262 - S262
  • [9] Successful Treatment of Digital Tip Necrosis in Rheumatoid Vasculitis With Anti-CD20 Antibody Rituximab
    Korkosz, Mariusz
    Krolczyk, Jaroslaw
    Telesinska-Jasiowka, Dorota
    Grodzicki, Tomasz
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2013, 19 (01) : 43 - 45
  • [10] Safety and Efficacy of an Anti-CD20 Monoclonal Antibody (Reditux (TM)) In Indian Patients with Seropositive Rheumatoid Arthritis
    Hegde, Arun
    Vasdev, Vivek
    Shanmuganandan, Krishnan
    Singh, Kavita
    Kartik, Sivasami
    Kumar, Abhishek
    [J]. INDIAN JOURNAL OF RHEUMATOLOGY, 2018, 13 (01) : 20 - 25
12345